Siren Biotechnology and Catalent Inc. entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.65 USD | -0.58% | -1.09% | +21.63% |
May. 16 | Argus Downgrades Catalent to Sell From Buy | MT |
May. 14 | Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.63% | 9.89B | |
+38.69% | 728B | |
+32.93% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+15.74% | 244B | |
+7.86% | 207B | |
-5.24% | 205B | |
+6.42% | 164B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer